Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Безопасное обращение с противоопухолевыми препаратами

Список литературы

  1. Fransman, W., Roeleveld, N., Peelen, S., de Kort, W., Kromhout, H., & Heederik, D. 2007. Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes. Epidemiology, 18(1): 112-119
  2. IARC. Agents Classified by the IARC Monographs, Volumes 1–102
  3. Kromhout, H., Hoek, F., Uitterhoeve, R., Huijbers, R., Overmars, R. F., Anzion, R., & Vermeulen, R. 2000. Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg, 44(7): 551-560
  4. Krstev, S., Perunicic, B., & Vidakovic, A. 2003. Work practice and some adverse health effects in nurses handling antineoplastic drugs. Med Lav, 94(5): 432-439
  5. McAbee, R. R., Gallucci, B. J., & Checkoway, H. 1993. Adverse reproductive outcomes and occupational exposures among nurses: an investigation of multiple hazardous exposures. AAOHN J, 41(3): 110-119.
  6. Meyer, H. W., & Skov, P. S. 2010. Occupational rhinosinusitis due to etoposide, an antineoplastic agent. Scand J Work Environ Health, 36(3): 266-267
  7. Mosteller, R. D. 1987. Simplified calculation of body-surface area. N Engl J Med, 317(17): 1098
  8. Queruau-Lamerie, T., Carrez, L., Decaudin, B., Bouchoud, L., Goossens, J. F., Barthelemy, C., Bonnabry, P., & Odou, P. 2011. Multiple-test assessment of devices to protect healthcare workers when administering cytotoxic drugs to patients. J Oncol Pharm Pract
  9. Sessink, P. J., Connor, T. H., Jorgenson, J. A., & Tyler, T. G. 2011. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract, 17(1): 39-48
  10. Walusiak, J., Wittczak, T., Ruta, U., & Palczynski, C. 2002. Occupational asthma due to mitoxantrone. Allergy, 57(5): 461
  11. Bos RP et al Mutagenicity of urine from nurses handling cytostatics drugs, influence of smoking. Int. Arch. Occup. nviron Health 50 (1982): 359-369
  12. Bos RP Sessink PJ. Biomonitoring of occupational exposures to cytostatic anticancer drugs. Rev. Inviron. Health 12 (1997): 43-58
  13. Nava C. Contributo alio studio della patologia comparsa in lavoratoria adetti alia produzione et alia somministrazione di citostatici. Boll. Chim. Farm. 123 (1984): 547-551
  14. Gabriele P et al. Undifferentiated nasopharyngeal-type carcinoma in a nurse handling cytostatic agents. Eur. J. Cancer В Oral Oncol. 29B (1993): 153
  15. Levin LI et al. Bladder cancer in a 39-year-old femal pharmacist. J. Natl. Cancer Inst. 85(1993): 1089-1091
  16. Hemminki К et al. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J. Epidemiol. Community Health 39 (1985): 141-147
  17. Falck К et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1 (1979): 1250-1251
  18. Benhamou S et al. Mutagenicity in urine from nurses handling cytostatic agents. Eur. J.Clin. Oncol. 22(1986): 1489-1493
  19. Cavallo D et al. Evaluation of genotoxic effects induced by the exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat. Res. 587 (2005): 45-51
  20. Ensslin AS et al. Urinary platinum in hospital personnel occupational^ exposed to platinum-containing antineoplastic drugs. Int. Arch. Occup. Environ. Health 65 (1994): 339-342
  21. Nygren O, Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int. Arch. Occup. Environ. Health 70 (1997): 209-214
  22. Burgaz S et al. Assessment of genotoxic damage in nurses occupational^ exposed to antineoplastics by the analysis of chromosomal aberrations. Hum. Exp. Toxicol. 21 (2002): 129-135
  23. FUChs J et al. DNA damage in nurses handling antineoplastic agents. Mutat. Res. 342 (1995): 17-23
  24. Crauste-Manciet S et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann. Occup. Hyg. 49 (2005): 619-628
  25. Delporte JP et al. Chemical contamination of the primary packaging of 5-fluorouracil rtu solutions commercially available on the Belgian market. Eur. Hosp. Pharm. 5 (1999): 119-121
  26. Kiffmeyer TK et al. External contamination of drug packaging. Suggestions for a cleaning procedure. Krankenhauspharmazie 22 (2001): 207-212 (in German)
  27. Favier В et al. Contamination of syringe plungers during the sampling of cyclophosphamide solutions. J. Oncol. Pharm. Pract. 11 (2005): 1-5
  28. Hansel S et al. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan. Int. Arch. Occup. Environ. Health 69 (1997): 109-114
  29. Harrison BR. Kloos MD. Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs. J. Oncol. Pharm. Practice 5 (1999): 61-66
  30. Hedmer M et al. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. J. Environ. Monit. 6 (2004): 979-984
  31. Hedmer M et al. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann. Occup. Hyg. 49 (2005): 629-637
  32. Hemminki К et al. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J. Epidemiol. Community Health 39 (1985): 141-147
  33. Hepp R, Gentschew G. External contamination of commercially available cytotoxic drug vials. Krankenhauspharmazie 1 (1998): 22-27 (in German)
  34. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 17 (1997): 163-165
  35. Hessel H et al. The genotoxic risk of hospital, pharmacy and medical personnel occupational^ exposed to cytostatic drugs - evaluation by the micronucleus assay Mutat. Res. 497 (2001): 101-109
  36. Jakab MG et al. Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J.Toxicol. Environ. Health A 62 (2001): 170-177
  37. Jordan К et al. Extravasation of chemotherapeutic agents: prevention and therapy. Dtsch. Med. Wochenschr. 130 (2005): 33-37 (in German)
  38. Jung D et al. Preparation of antineoplastic drug solutions in laminar flow cabinets - effects on pregnancy and offspring of pharmacy personnel. Krankenhauspharmazie 22 (2001): 3-10 (in German)
  39. Larson RR et al. Development of an HPLC method for simultaneous analysis of five antineoplastic agents. Appl. Occup. Environ. Hyg. 18 (2003a): 109-119
  40. Larson RR et al. A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl. Occup. Environ. Hyg. 18 (2003b): 120-131
  41. Laurenzi L et al. Cutaneous bacterial colonization, modalities of chemotherapeutic infusion, and catheter-related bloodstream infection in totally implanted venous access devices. Support Care Cancer 12 (2004): 805-809
  42. Medicines and Healthcare products regulatory Agency. Rules and Guidance fa Pharmaceutical Manufacterers and Distributors 202. London. The Stationery Office (2002) (Rev. to Annex 1 in preperation) September 2003
  43. Lawrence HJ et al. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother. Pharmacol. 23 (1989): 316-318
  44. Lee AYY et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J. Clin. Oncol. 24 (2006): 1404-1408
  45. Levin LI et al. Bladder cancer in a 39-year-old femal pharmacist. J. Natl. Cancer Inst. 85(1993): 1089-1091
  46. Levin M et al. Mitoxantrone extravasation and tissue necrosis. Am J. Health. Syst. Pharm. 53(1996): 1192,1194
  47. Loth TS. Eversmann WW Jr. Treatment methods for extravasation of chemotherapeutic agents: a comparative study. J. Hand. Surg. [AM] 11 (1986): 388-396
  48. Mader RM et al. Exposure of oncologic nurses to methotrexate in the treatment ol osteosarcoma. Arch. Environ. Health 51 (1996): 310-314
  49. Opiolka S et al. Traces of high-effective pharmaceuticals in indoor air of preparation rooms: theory - detection-results. Krankenhauspharmazie 22 (2001): 317-324 (in German)
  50. OSHA, Controlling occupational exposure to hazardous drugs. In: OSHA Technical manual (OSHA instructions CPL 2-20B CH-4). Washington. DC. Directorate of Technical Support, Occupational Safety and Health Administration (1995): Chapter 21
  51. OSHA. Technical Manual. TED 1-0.15A (1999): Section VI, Chapter 2
  52. Ozdemir FA et al. Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCI and epirubicin-HCI in the same infusion solution. Cancer Chemother. Pharmacol. 56 (2005): 529-53
  53. Paul H et al. Environmental monitoring for contamination with antineoplastic agents. Krankenhauspharmazie 4 (1998): 181-186 (in German)
  54. Pethran A et al. Wipe samples of workplaces with cytotoxic drug exposure. Krankenhauspharmazie 22 (2001): 11-15 (in German)
  55. Pethran A et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int. Arch. Occup. Environ Health 76 (2003): 5-10
  56. Pilger A et al. Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupational^ exposed to cytostatic drugs. Int. Arch. Occup. Environ. Health 73 (2000): 442-448
  57. NF Izmerov, GI.Tikhonova, NV Lebedeva Сongenital malformations in children and paternal occupational exposures. EPICOH – 2005 Conf. Univers. of Bergen. Bergen, Norway. - 26-28 Sept.2005// Book of.Abstr. - Bergen, 2005. - P.89.
  58. G.I. Tikhonova Paternal occupational exposures and birth defects in children. IСОН 2006 Book of abst. 28th Int. Congress on Occup. Health. “Renewing a century of commitment to a health, safer and productive working life” Milan, Italy, June 11-16, 2006, р. 136
  59. Измерова, Н. И., Кузьмина, Л. П., Королева, Е. П., & Тихонова, Г. И. 2009. Меры по профилактике нарушений состояния здоровья медицинского персонала при работе с цитостатиками, XIII Российский онкологический конгресс. Москва, Российская Академия Государственной Службы.
  60. Тихонова, Г. И. 2004. Влияние условий труда родителей на состояние здоровья детей (эпидемиологические исследования), Автореф.дисс. на соиск.уч.ст. докт. биол.наук: 48. Москва.
  61. Тихонова Г.И. Влияние условий труда родителей на состояние здоровья детей (эпидемиологические исследования) Автореф.дисс. на соиск.уч.ст. докт. биол.наук – М. - 2004.:48 с.
  62. Тихонова Г.И. Оценка риска развития редких форм патологии у детей как следствия профессиональной экспозиции родителей // Бюл. Науч. Совета Медико-экологические проблемы работающих. - М. 2004. - № 1. - С.65-69;
  63. Тихонова Г.И., Рубцова Н.Б., Яковлева Т.П. Условия труда родителей как фактор риска развития врожденных пороков у детей Ж.Безопасность жизнедеятельности. 2006. - №2. - С.52-57.]

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Table of contents

Данный блок поддерживает скрол*